Windtree Therapeutics, Inc. · OTC:WINT

Windtree Therapeutics — Investor Presentation (August 2022)

42 slides from Windtree Therapeutics's investor presentation, Aug 11, 2022

  1. Slide 1: Windtree Therapeutics Company Overview

    Windtree Therapeutics N Company Overview August 11, 2022 Sse we WINDTREE (NASDAQ: WINT)

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation includes forward-looking statements within the meaning of Section 27Aof the Securities Actof 1933, as amended, and Section 21E ofthe Securities Exchange Act of 1934, as amended. These statements, among other things, include statements about the Company's

  3. Slide 3: Windtree Therapeutics and Istaroxime Highlights

    Windtree Therapeutics and Istaroxime Highlights v v Biopharmaceutical company with advanced clinical focused on significant acute CV markets with high unmet needs and with supportive regulatory paths and designations (NASDAQ: WINT) Through three Phase 2 global studies, lead asset istaroxime has cons

  4. Slide 4: Pipeline

    Pipeline Lead Products _ Indication Phase Istaroxime Acute Heart Failure Phase 2b Istaroxime Early Cardiogenic Shock Phase 2 Oral SERCA2a Rakai Chronic HF; potentaly HFpEF ——_—Prectnical KL4Surfactant— COviO 19Pilot, Possible invasive pace > COVID19 ‘Tx for RDS in neonates ‘AEROSURF We sufeclant Dru

  5. Slide 5: Strategy for Value Creation

    Strategy for Value Creation 2022 2023 2024 Q2 Q3 Q4 Qi Q2 Q3 Q4 Qi Q2 Q3 Istaroxime Cardiogenic Shock FDAEOP2 Phase 2 ' par (SEISMIC) ~| Early Cardiogenic Shock Positive | Registration Study* 4 Results ees sits Istaroxime Heart Failure Acute Heart Failure Study ~18 month o execute; Ph, potenti! (tra

  6. Slide 6: Istaroxime: Early Cardiogenic Shock

    Istaroxime Early Cardiogenic Shock Additional potential indication in active clinical development

  7. Slide 7: Cardiogenic Shock

    Cardiogenic Shock Asevere presentation of heart failure characterized by very low blood pressure and hypoperfusion accompanied by high filling pressures of the heart and decreased urine output. Itisa treatment emergency » Caused by severe impairment of cardiac function that results in diminished car

  8. Slide 8: Early Cardiogenic Shock Treatment: Market Research

    jarket Research’ Early Cardiogenic Shock Treatment Istaroxime Potential Opportunity to Address Significant Unmet Need ~ No satisfactory pharmacological intervention to reverse the conditions Available therapies have unwanted side effects such as risk for arrhythmias, decreasing blood pressure, renal

  9. Slide 9: Istaroxime: Novel First-in-Class Therapy

    Istaroxime — Novel First-in-Class Therapy Novel intravenous agent designed to improve systolic contraction and diastolic relaxation of the heart Dual Mechanism of Action ‘Stimulation of SERCA2a activity Inhibition of the sodium- ® enhances calcium reuptake potassium pump and effects on i tho sodumca

  10. Slide 10: Rationale for Istaroxime in Cardiogenic Shock Came from AHF Phase 2 Trials

    Rationale for Istaroxime in Cardiogenic Shock Came from AHF Phase 2 Trials E/e’ (cardiacfilling pressure) Systolic Blood Pressure (SBP) Istaroxime 1.0 yg/kg/min vs. placebo Istaroxime 1.0 yg/kgimin vs. placebo 7 * I 1 et + paue= 0011 ‘ i. * pales <0. 006 Improved : cardiac function ; — | si, and SBP

  11. Slide 11: Early Cardiogenic Shock Treatment: Accelerated Pathway

    Early Cardiogenic Shock Treatment Istaroxime Potential Opportunity for Accelerated Pathway Potential for a relatively fast and less expensive developmental and regulatory pathway Sponsors are potentially not required to show benefit other than an FDA Regulatory increase in blood pressure to support

  12. Slide 12: SEISMiC Early Cardiogenic Shock Study

    SEISMiC Early Cardiogenic Shock Study Clinical strategy: Start development with patients in early cardiogenic shock caused by severe heart failure ] p 60 patients in early cardiogenic shock (SBP 75-90mmHg) with AHF Study drug was infused for 24 hours in a 1:1 randomization to placebo or istaroxime.

  13. Slide 13: Difference in SBP Profile

    020 Difference in SBP Profile Systolic Blood Pressure AUC through 6 Hours - mITT Population Bi staroxime Placebo mmHg) SBP ( in Change from Baseline i o os 1 iS 2s 3 SaaS SSS 8g Hours from Infusion Inititation _ WINDTREE fa)

  14. Slide 14: Secondary Results

    \ Secondary Results _ Systolic BP Improvements Persisted over 24 Hours Systolic Blood Pressure mITT Population 20 46 —*Istaroxime 3 © Placebo z E & re 3 £ 6 { p=0.025 for AUC Atal ° 0 12 24 Hours from Infusion initiation a6 WINDTREE “

  15. Slide 15: Cardiac Function Improvement

    Cardiac Function Improvement Echocardiography demonstrated improvements in key systolic and diastolic cardiac function measures including: * Cardiac index significantly increased » Stroke volume index substantially increased (4 mL/m?) approaching statistical significance * Other echocardiographic me

  16. Slide 16: Treatment was Associated with a Favorable Renal Profile

    Treatment was Associated with a Favorable Renal Profile Renal function was not decreased in istaroxime treated patients ,—_________ Estimated Glomerular Filtration Rate mITT Population {GER (riini3.73m%) Fr a Z Boa 3 E coils é = © Placebo 7 a a a on ore oe i 2 Pa % @ Pa 2 ee ra ours trom nuston inio

  17. Slide 17: Comparison of Doses

    b Comparison of Doses 1.0 pg/kg/min Produced a Favorable Effect on SBP 4.0 ugikgimin dosing was associated with: ~ Early, rapid SBP increase and improvement in more echocardiographic assessments of cardiac function + More favorable adverse event, serious adverse event and clinical event profile 21.0

  18. Slide 18: SEISMIC Results Summary

    SEISMIC Results Summary SEISMIC was a positive study in early cardiogenic shock patients v Systolic blood pressure significantly increased within the first 6 hours of initiating the infusion (p=0.017) and the increase was maintained throughout the 24-hour infusion (p=0.025) » SBP increases were rapi

  19. Slide 19: Relevance to the Acute Heart Failure (AHF) Program

    Na Relevance to the Acute Heart Failure (AHF) Program » The early cardiogenic shock trial results are consistent with Windtree’s Phase 2 AHF studies and complementary to further advancement in AHF. » While SEISMIC was an early cardiogenic shock study, the patients studied had very severe AHF providi

  20. Slide 20: Cardiogenic Shock Development Strategy

    Cardiogenic Shock Development Strategy SEISMIC Extension Study = Extended and titrated dosing for optimization SE ic ‘= Additional characterization Phase 3* ISMi Of SERCAZA effect = Execute EOP2 meeting Study with these 3 studies augmented by AHF Proof of Concept ey safety data base, etc. SCAI Stage

  21. Slide 21: Plan for Dose Optimization: Extension Study

    Plan for Dose Optimization — Extension Study Following the positive results in the early cardiogenic shock study, an extension study is planned to support ongoing development in early cardiogenic shock and acute heart failure Study objectives: v Advance the characterization of the physiology associa

  22. Slide 22: Istaroxime: Acute Heart Failure

    Istaroxime Dual Mechanism SERCA2a Activator Acute Heart Failure

  23. Slide 23: Heart Failure: Large, Growing Market But Underserved

    Heart Failure - Large, Growing Market But Underserved The prevalence and mortality of heart failure is high and increasing #1 cause of U.S. Annual Admissions Patients hospitalization ~1.3M us 7Mus . wi in patients ~1.5M ev. 25M * wortawiae > 65 years old ES ~7T% (oy >$18B co 0 In-patient mortality a

  24. Slide 24: Acute Heart Failure: Significant Unmet Clinical Need

    Acute Heart Failure — Significant Unmet Clinical Need tient Management Goals urrent Treatment Options * Clinical objectives for AHF » Current approaches to acutely improve cardiac patient management include: function are associated with unwanted effects: Relieve pulmonary congestion Heart rhythm dis

  25. Slide 25: Istaroxime AHF Phase 2a & 2b Studies

    Istaroxime AHF Phase 2a & 2b Studies * Primary: PCWP significantly improved Phase * Stroke Vol & SBP ~ significantincrease 2a n=120 Dosing= 6 hour + Heart Rate (HR) - lowered ADHF Patients 0.5, 1, 1.5 ygkgimin Infusion Phase n=120 Dosing= 24 hour 2b ADHF Patients 0.5, 1.0 voksimin Infusion (aysenea

  26. Slide 26: Primary Endpoint Achieved

    Primary Endpoint Achieved Significant Changes in E/e' Ratio’ and Stroke Volume WINDTREE Istaroxime 0.5 ug/kg/min vs. placebo + Placebo -Cohor infusion period * pwvalue = 0.029 —eisrcrine 15 voto Infusion period Ele’ |), Et echocarsograpicassessmentotPCWP; Note Oatashown.as means andstandard ears Ist

  27. Slide 27: Systolic Blood Pressure Increased and Renal Function Tended to Improve

    Systolic Blood Pressure Increased During Treatment and Renal Function Tended to Improve Istaroxime 0.5 ug/kgimin vs. placebo Istaroxime 1.0 ug/kgimin vs. placebo Le Systolic 3° + paar oon Hi Blood = * rad ag? Pressure 5 ° H (SBP) Zo i: Bs a é é E © Pete Cont? elaine 109K » 6 eo ; is] GFR i Lal (Rena

  28. Slide 28: Heart Rate Decreased and No Increases in Cardiac Troponins

    Heart Rate Decreased and No Increases in Cardiac Troponins Istaroxime 0.5 yg/kgimin vs. placebo Istaroxime 1.0 ug/kgimin vs. placebo i, Heart re Rate ts a *pralue= 0.014 a *pvalue=0.011, 2 eel at place Os a Pasts-Cinatt metroid iainn Sree hante-tomn? gtavexnet sean eTnT-0t0 24 hours 7 eTnT=24to 72 h

  29. Slide 29: Favorable Profile Observed with 24-hour Holter Monitoring

    Favorable Profile Observed with 24-hour Holter Monitoring Clinically Significant Arrhythmias 1208 250% 708% 10am 108% aca. sao | 220% 200% 200% Eom: 288 ee, 100% 100% 40% om 24% 24% 24% 00% oo L — a Baseline ay 1 (rtsen) ay 2 Bassiee ay (sor) a2 sPacebo-Cahot + alascrime 05 vakgimn Placebo - Conon 2

  30. Slide 30: Istaroxime: Acute Heart Failure Phase 2c

    2c Istaroxime — Acute Heart Failure Objective: Optimize therapy and employ study enrichment strategies to create strong Phase 3 and partnership position Execute an additional study designed to complete Phase 2 and inform Phase 3 - 300 patients, 60 centers globally Enrich therapeutic impact by levera

  31. Slide 31: Next Generation, Oral SERCA2a Activators Platform

    Next Generation, Oral SERCA2a Activators Acute and Chronic Heart Failure Platform The Company also has pre-clinical programs on product candidates including: Selective SERCA2a Dual Mechanism, (SERCA2a & Na+/K+) Activators Compounds + Oral & i.v. therapies for chronic “Next generation istaroxime” as

  32. Slide 32: Summary

    Summary rg Istaroxime has produced positive, differentiating data in three Phase 2 studies for two separate and complementary indications. These markets have significant unmet needs, and no known other late-stage programs in development to address the acute decompensated patient ~ The data is consis

  33. Slide 33: Financial Summary & Capitalization

    Financial Summary & Capitalization Cash & Equivalents of ~$11.4 million as of June 30, 2022 Common Equivalents Securities as of August 11, 2022 Common Stock 30,627,878 Options (WAEP $7.84) 4,046,604 Restricted Stock Units 560,900 Warrants (WAEP $6.64) 16,546,336 Fully Diluted Equivalents. 51,781,718

  34. Slide 34: Strategy for Value Generation

    Strategy for Value Generation Communicate Our Milestones Transactions WA Optimization ie Secure focused BD Bring in new, well- transactions fordeal revenue Suited development and non-dilutive financial supportof clinical opportunities and development transactions Progress heart failure platformto an

  35. Slide 35: Slide 35

  36. Slide 36: Appendix

    Appendix se ce WINDTREE

  37. Slide 37: Istaroxime Unique Opportunity With Attractive Risk / Return Profile

    Istaroxime Unique Opportunity With Attractive Risk / Return Profile @ Hichy consistent results across 3 @© Attractive profile as the only acute heart failure or shock drug that has controlled Phase 2 studies (and been shown to significantly improve cardiac function of a failing heart, 300 patients d

  38. Slide 38: Istaroxime AHF Phase 2b Adverse Events

    Istaroxime AHF Phase 2b Adverse Events Pooled placebo _—Istaroxime 0.6 mg/Kgimin _Istaroxime 1.0 mg/Kgimin (n=39) (n=41) (n=40) All adverse events 23 (59.0%) 31 (75.6%) 33 (625%) ‘Adverse events leading to discontinuation 1 (26%) : 4(100%) Serious adverse events 206.1%) 2(49%) 6(150%) Cardiac death

  39. Slide 39: SEISMIC: Serious Adverse Events and Adverse Drug Reactions

    SEISMIC: Serious Adverse Events and Adverse Drug Reactions Istaroxime Placebo (N=29) (N=31) All adverseevents 27 (93%) 25 (81%) Seriousadverse events 6 (19%) Cardiac arrest ° Cardiac failure 2 (6%) Cardiac failure acute 1 (3%) ventric i 1(3%) Cardiac artery 1(3%) Ventricular fibrillation Ventricular

  40. Slide 40: SEISMiC: Safety and Efficacy More Favorable with 1.0 vs 1.5 ug/kg/min

    SEISMiC: Safety and Efficacy Appeared More Favorable with the 1.0 vs 1.5 pg/kg/min and Placebo 1.0 ug/kg/min dosing was associated with: Istaroxime Istaroxime Placeb clinical Events by Dose Statistic Nest), Sroka rt cao [SBP AUC 0-24hrs LS-Means(SE)* 209.9(27.38) 282.7 (35.79) 304.1 (44.11) ‘Worseni

  41. Slide 41: Acute Heart Failure: Significant Unmet Clinical Need

    Acute Heart Failure Significant Healthcare Issue with Significant Unmet Clinical Need * Patients with low blood pressure (SBP) and peripheral hypoperfusion are high risk, challenging patients. These patients are also generally resistant to diuretic therapy and often discharged in a sub-optimal state

  42. Slide 42: Istaroxime Phase 2a (HORIZON-HF) Study

    Istaroxime Phase 2a (HORIZON-HF) Study + Multicenter, double blind, placebo-controlled, doses 6-hour infusion of istaroxime 0.5, 1.0, 1.5 ug/kg/min, conducted in the EU ~ Hospitalized with AHF, with criteria including: LVEF s 35% ‘SBP 90-150 mmHg + N=120 (30/group) * Significant improvement in PCWP,

Windtree Therapeutics — Investor Presentation (August 2022) on 6ix